Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

31.91 -0.41 (-1.27%)
Delayed Quote Updated: 9:56 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
4 High-Risk Stocks Built for Big Returns ↗
These speculative investments could turbocharge a portfolio to market-beating returns. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
From Pomerantz LLP
Via GlobeNewswire
Agios Pharmaceuticals (NASDAQ:AGIO) Surges on Q2 Revenue Beat Driven by PYRUKYND Sales ↗
Via Chartmill
Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings Beat Drives Stock Rally ↗
Via Chartmill
Topics Earnings
News headline image
Agios Pharmaceuticals Q2 Earnings Call Highlights ↗
Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company... 
Via MarketBeat
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week ↗
An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards. 
Via The Motley Fool
News headline image
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) ↗
The company received some good news on its most important drug today. 
Via The Motley Fool
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss ↗
Agios Pharmaceuticals (NASDAQ:AGIO) used an investor webcast tied to the 2026 European Hematology Association Congress in Stockholm to highlight new clinical data for mitapivat across thalassemia and... 
Via MarketBeat
News headline image
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
From Avanzanite Bioscience B.V. and Agios Pharmaceuticals, Inc.
Via Business Wire
News headline image
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances ↗
Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently... 
Via MarketBeat
News headline image
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) ↗
The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline. 
Via The Motley Fool
News headline image
Agios (AGIO) Q1 2026 Earnings Call Transcript ↗
Agios (AGIO) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday ↗
There's power in the company's No. 1 molecule. 
Via The Motley Fool
News headline image
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) ↗
A rival company's trial results had a negative impact on Agios' stock this week. 
Via The Motley Fool
News headline image
Agios (AGIO) Q3 2024 Earnings Call Transcript ↗
Agios (AGIO) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agios (AGIO) Q2 2025 Earnings Call Transcript ↗
Agios (AGIO) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Agios (AGIO) Q3 2025 Earnings Transcript ↗
Agios (AGIO) Q3 2025 Earnings Transcript 
Via The Motley Fool
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Here's Why Agios Pharmaceuticals Crashed 23% Today ↗
The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow. 
Via The Motley Fool
What's going on in today's session ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? ↗
.Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease. 
Via Benzinga
News headline image
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today ↗
The young drugmaker's sickle cell treatment is receiving special consideration from the United States' top drug regulator. 
Via The Motley Fool
News headline image
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything ↗
Focused on therapies for rare blood disorders, this biotech saw a notable insider sale amid ongoing clinical development efforts. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Agios (AGIO) Q4 2025 Earnings Call Transcript ↗
Agios (AGIO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.